Welcome to our dedicated page for RAPT Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on RAPT Therapeutics stock.
RAPT Therapeutics, Inc. (NASDAQ: RAPT) is a clinical-stage biopharmaceutical company specializing in immunology-based treatments. Focused on developing and commercializing oral small molecule therapies, RAPT Therapeutics aims to address significant unmet medical needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company creates highly selective small molecules designed to modulate critical immune drivers underlying these conditions.
RAPT Therapeutics has two main drug candidates: FLX475 (tivumecirnon) and RPT193 (zelnecirnon). FLX475 targets the C-C motif chemokine receptor 4 (CCR4) and is designed to inhibit the migration of regulatory T cells into tumors, enhancing the immune response against cancer. RPT193, also targeting CCR4, focuses on inhibiting type 2 T helper cells in inflamed tissues, offering potential relief for inflammatory diseases like atopic dermatitis and asthma.
In recent developments, RAPT Therapeutics reported promising Phase 2 data for FLX475 in combination with pembrolizumab for non-small cell lung cancer (NSCLC) patients. The company also emphasized FLX475's potential in other cancers, including head and neck cancer, gastric cancer, and non-Hodgkin lymphoma. Despite a clinical hold placed by the FDA on the Phase 2 trials for zelnecirnon due to a serious adverse event, RAPT continues to investigate and aims to resolve the issue.
Financially, RAPT Therapeutics maintains a strong cash position, reporting $158.9 million in cash and equivalents by the end of 2023. The company is diligently working to advance its clinical programs and explore additional targets in the discovery stage, ensuring a robust pipeline for future developments.
RAPT Therapeutics announced positive topline results from its Phase 1b trial of RPT193 for moderate-to-severe atopic dermatitis. After four weeks, patients showed a 36.3% improvement in the Eczema Area and Severity Index (EASI) compared to 17.0% in the placebo group. Notably, a 53.2% improvement was recorded six weeks post-treatment. RPT193 was well tolerated with no serious adverse events. RAPT plans to advance RPT193 into a Phase 2b trial in atopic dermatitis and a Phase 2a trial in asthma.
RAPT Therapeutics (Nasdaq: RAPT) announced it will release top-line results from its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis on June 14, 2021. This key data announcement signifies the company's ongoing commitment to addressing unmet medical needs in inflammatory diseases. The results will be shared during a conference call at 8:30 a.m. ET, which will be accessible via a live webcast. RAPT is developing targeted oral therapies focusing on CCR4, with RPT193 as a notable candidate in its pipeline.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO Brian Wong will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 3:00 pm Eastern Time. The event aims to discuss the company’s advancements in developing oral small molecule therapies for oncology and inflammatory diseases. Interested parties can access the live webcast and archived recording on the RAPT Therapeutics website. The company is focused on developing selective small molecules targeting critical immune drivers, including drug candidates FLX475 and RPT193.
RAPT Therapeutics reported a net loss of $16.5 million for Q1 2021, up from $13.1 million in Q1 2020. Research and development expenses rose to $13.8 million due to increased clinical trial costs and personnel expenses. General and administrative expenses increased to $4.0 million, impacted by higher stock-based compensation and insurance costs. The company is progressing in its oncology and inflammation programs, highlighting recent preclinical data and the completion of enrollment in a Phase 1b trial for RPT193. Cash and equivalents stood at $98.4 million as of March 31, 2021.
RAPT Therapeutics has completed enrollment in its Phase 1b clinical trial of RPT193 for moderate to severe atopic dermatitis, with results expected by mid-2021. The trial aims to establish safety and clinical efficacy through multiple endpoints, including the Eczema Area and Severity Index and pruritis scale. An encouraging outcome may position RPT193 as a viable oral treatment option against existing injectable therapies, targeting significant unmet needs in inflammatory diseases.
RAPT Therapeutics (Nasdaq: RAPT) announced its financial results for Q4 and the year ending December 31, 2020. The company reported a net loss of $12.7 million for Q4 2020, slightly better than the $13.2 million loss in Q4 2019. Annual net loss increased to $52.9 million from $43 million in 2019. Research and development expenses rose to $45.5 million in 2020, driven by clinical trial costs for FLX475 and RPT193. As of December 31, 2020, cash and equivalents totaled $111.5 million. Key clinical advancements were noted for both lead programs, with upcoming data readouts expected in 2021.
RAPT Therapeutics (RAPT) reported promising data from preclinical studies to be presented at the American Association for Cancer Research annual meeting. Key findings include the ability of CCR4 antagonists to enhance CAR T-cell therapy's efficacy in solid tumors, with a significant increase in survival rates in murine models. Additionally, small-molecule HPK1 inhibitors demonstrated enhanced T-cell responses, while GCN2 inhibitors showed potential to restore immunity in the tumor microenvironment. These developments highlight RAPT's ongoing commitment to advancing immunology-based therapies for cancer treatment.
SOUTH SAN FRANCISCO, Calif., March 3, 2021 - RAPT Therapeutics (Nasdaq: RAPT) announced CEO Brian Wong will speak at two investor conferences this month. The H.C. Wainwright Global Life Sciences Conference features a company presentation available on March 9 at 7:00 am ET. Wong will also participate in the 33rd Annual Roth Conference on March 15 at 2:00 pm ET, discussing novel immuno-oncology targets. RAPT specializes in oral small molecule therapies for oncology and inflammatory diseases, focusing on advanced drug candidates like FLX475 and RPT193.
RAPT Therapeutics announced that its CEO, Brian Wong, M.D., Ph.D., will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 12:00 PM ET. The company focuses on immunology-based therapies for oncology and inflammatory diseases.
RAPT is developing small molecule therapies, including FLX475 and RPT193, targeting C-C motif chemokine receptor 4 (CCR4). For more details, visit the company's website.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Brian Wong, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 3:40 PM Eastern Time. The company focuses on developing oral small molecule therapies for oncology and inflammatory diseases. RAPT has advanced drug candidates targeting C-C motif chemokine receptor 4 (CCR4) and is exploring additional targets in early development. For those interested, the presentation will be available live and archived on their website.
FAQ
What is the current stock price of RAPT Therapeutics (RAPT)?
What is the market cap of RAPT Therapeutics (RAPT)?
What does RAPT Therapeutics do?
What are the main drug candidates of RAPT Therapeutics?
What recent achievements has RAPT Therapeutics made?
What financial condition is RAPT Therapeutics in?
What is FLX475?
What is RPT193?
What is the status of the Phase 2 trials for zelnecirnon?
What recent financial results has RAPT Therapeutics reported?
How is RAPT Therapeutics funded for its ongoing operations?
What are the primary focuses of RAPT Therapeutics' research?
